REAL-TIME CANCER THERAPY MONITORING – Cadex Genomics | Bill Haack & Greg Schafer

Trends in Med Tech

Bill Haack, CEO and Greg Schafer, CCO are part of a seasoned team that is leading an initiative to transform the way in which responsiveness to cancer treatment is assessed. If all goes to plan, the technology being developed at Cadex Genomics could impact the course of treatment for millions of late-stage (solid state) cancer patients worldwide.

At the heart of the matter is a blood-based assay called Alibrex which uses a low-cost PCR protocol to examine cell-free DNA. By comparing two blood draws taken ~2 weeks apart in patients being treated for cancer, the test is used to determine whether a tumor is responding to that treatment. The key is in its 24-hour turn-around time to assess responsiveness, which allows quicker adjustments in treatment than currently possible and may help to prevent side effects associated with unnecessary or ineffective therapies.

Though still in clinical development at sites in the US, Canada and Israel, early results have shown the test to be highly specific, meaning that it correctly identifies non-responsive (disease-progressing) patients 100% of the time, thereby flagging patients who require a different course of treatment.

With a new funding round well underway they plan to complete algorithm validation by 2020/early 2021 and to begin commercialization in mid-2021. We wish them all the best as they roll out this important development in oncology molecular diagnostics.

Find out more about Cadex Genomics:
w: https://www.cadexgenomics.com/en/home
LI: https://www.linkedin.com/company/cadexgenomics/
Twitter: https://twitter.com/cadexgenomics?lang=en
FB: https://www.facebook.com/cadexgenomics/
E: [e-mail], [e-mail]